{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:20:21Z","timestamp":1788520821340,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hengrui Key Program","award":["FYHR2024-016"],"award-info":[{"award-number":["FYHR2024-016"]}]},{"name":"Fuyang City People's Hospital","award":["FK20254617"],"award-info":[{"award-number":["FK20254617"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16377-5","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:15:38Z","timestamp":1781950538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sanguinarine as a multi-target therapeutic candidate for laryngeal cancer: insights from network pharmacology, molecular dynamics and in vitro validation"],"prefix":"10.1186","volume":"26","author":[{"given":"Meng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"3","key":"16377_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834. From NLM.","journal-title":"CA Cancer J Clin"},{"key":"16377_CR2","doi-asserted-by":"publisher","unstructured":"Hut AR, Boia ER, Para D, Iovanescu G, Horhat D, Mik\u0161a L, Chiriac M, Galant R, Motofelea AC, Balica NC. Laryngeal Cancer in the Modern Era: Evolving Trends in Diagnosis, Treatment, and Survival Outcomes. J Clin Med. 2025;14(10). https:\/\/doi.org\/10.3390\/jcm14103367. From NLM.","DOI":"10.3390\/jcm14103367"},{"key":"16377_CR3","doi-asserted-by":"publisher","unstructured":"Shires CB, Sebelik ME. Immunotherapy monotherapy for patients with recurrent nonmetastatic larynx cancer who refuse salvage total laryngectomy. Front Oncol. 2025;15:1626880. https:\/\/doi.org\/10.3389\/fonc.2025.1626880. From NLM.","DOI":"10.3389\/fonc.2025.1626880"},{"issue":"10","key":"16377_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/cncr.29241","volume":"121","author":"DI Rosenthal","year":"2015","unstructured":"Rosenthal DI, Mohamed AS, Weber RS, Garden AS, Sevak PR, Kies MS, Morrison WH, Lewin JS, El-Naggar AK, Ginsberg LE, et al. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015;121(10):1608\u201319. https:\/\/doi.org\/10.1002\/cncr.29241. From NLM.","journal-title":"Cancer"},{"issue":"5","key":"16377_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269\u201382. https:\/\/doi.org\/10.1038\/nrc.2018.11. From NLM.","journal-title":"Nat Rev Cancer"},{"key":"16377_CR6","doi-asserted-by":"publisher","unstructured":"Jiang Q, Xiao J, Hsieh YC, Kumar NL, Han L, Zou Y, Li H. The Role of the PI3K\/Akt\/mTOR Axis in Head and Neck Squamous Cell Carcinoma. Biomedicines. 2024;12(7). From NLM. https:\/\/doi.org\/10.3390\/biomedicines12071610. From NLM.","DOI":"10.3390\/biomedicines12071610"},{"key":"16377_CR7","doi-asserted-by":"publisher","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144 (5):646\u2013674. From NLM. https:\/\/doi.org\/10.3390\/biomedicines12071610. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013. From NLM. https:\/\/doi.org\/10.3390\/biomedicines12071610.","DOI":"10.1016\/j.cell.2011.02.013"},{"issue":"11","key":"16377_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682\u201390. https:\/\/doi.org\/10.1038\/nchembio.118. From NLM.","journal-title":"Nat Chem Biol"},{"key":"16377_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.phymed.2017.08.006","volume":"34","author":"S Galadari","year":"2017","unstructured":"Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Molecular targets and anticancer potential of sanguinarine-a benzophenanthridine alkaloid. Phytomedicine. 2017;34:143\u201353. https:\/\/doi.org\/10.1016\/j.phymed.2017.08.006. From NLM.","journal-title":"Phytomedicine"},{"key":"16377_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/pros.21409","volume":"72","author":"M Sun","year":"2012","unstructured":"Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, et al. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 2012;72:82\u20139. https:\/\/doi.org\/10.1002\/pros.21409. From NLM.","journal-title":"Prostate"},{"key":"16377_CR11","first-page":"96","volume":"1","author":"KC Godowski","year":"1989","unstructured":"Godowski KC. Antimicrobial action of sanguinarine. J Clin Dent. 1989;1:96\u2013101.","journal-title":"J Clin Dent"},{"issue":"24","key":"16377_CR12","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.2174\/1381612824666180829100601","volume":"24","author":"C Fu","year":"2018","unstructured":"Fu C, Guan G, Wang H. The Anticancer Effect of Sanguinarine: A Review. Curr Pharm Des. 2018;24(24):2760\u20134. https:\/\/doi.org\/10.2174\/1381612824666180829100601.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"16377_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4155\/fmc-2017-0041","volume":"9","author":"IW Achkar","year":"2017","unstructured":"Achkar IW, Mraiche F, Mohammad RM, Uddin S. Anticancer potential of sanguinarine for various human malignancies. Future Med Chem. 2017;9(9):933\u201350. https:\/\/doi.org\/10.4155\/fmc-2017-0041. From NLM.","journal-title":"Future Med Chem"},{"key":"16377_CR14","doi-asserted-by":"publisher","first-page":"116406","DOI":"10.1016\/j.biopha.2024.116406","volume":"173","author":"LJ Huang","year":"2024","unstructured":"Huang LJ, Lan JX, Wang JH, Huang H, Lu K, Zhou ZN, Xin SY, Zhang ZY, Wang JY, Dai P, et al. Bioactivity and mechanism of action of sanguinarine and its derivatives in the past 10 years. Biomed Pharmacother. 2024;173:116406. https:\/\/doi.org\/10.1016\/j.biopha.2024.116406. From NLM.","journal-title":"Biomed Pharmacother"},{"key":"16377_CR15","doi-asserted-by":"publisher","unstructured":"Jain NK, Chandrasekaran B, Khazaleh N, Jain HK, Lal M, Joshi G, Jha V. Computational Network Pharmacology, Molecular Docking, and Molecular Dynamics to Decipher Natural Compounds of Alchornea laxiflora for Liver Cancer Chemotherapy. Pharmaceuticals (Basel). 2025;18(4). https:\/\/doi.org\/10.3390\/ph18040508. From NLM.","DOI":"10.3390\/ph18040508"},{"key":"16377_CR16","doi-asserted-by":"publisher","unstructured":"Wu Y, Liang Y, Liang J, Sun W, Zhang Q, Li MY. Systematic deciphering of ATBC nephrotoxicity mechanisms via machine learning and single-cell analysis. Med Bull. 2026;1\u201314. https:\/\/doi.org\/10.1002\/mdb2.70027. From NLM.","DOI":"10.1002\/mdb2.70027"},{"key":"16377_CR17","doi-asserted-by":"publisher","unstructured":"Wu Y, Liang Y, Liang J, Zengin G, Zhang Q, Li MY. Potassium sorbate triggers kidney injury via dysregulated intercellular communication: a study combining network toxicology, machine learning, molecular docking, and single-cell RNA sequencing. iMetaMed. 2025;1:1\u201316. https:\/\/doi.org\/10.1002\/imm3.70017.\u00a0 From NLM.","DOI":"10.1002\/imm3.70017"},{"issue":"7","key":"16377_CR18","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384\u2013421. https:\/\/doi.org\/10.3390\/molecules200713384. From NLM.","journal-title":"Molecules"},{"issue":"4","key":"16377_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41596-021-00676-1","volume":"17","author":"H Fu","year":"2022","unstructured":"Fu H, Chen H, Blazhynska M, Goulard Coderc de Lacam E, Szczepaniak F, Pavlova A, Shao X, Gumbart JC, Dehez F, Roux B, et al. Accurate determination of protein:ligand standard binding free energies from molecular dynamics simulations. Nat Protoc. 2022;17(4):1114\u201341. https:\/\/doi.org\/10.1038\/s41596-021-00676-1. From NLM.","journal-title":"Nat Protoc"},{"key":"16377_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s10147-019-01435-9","volume":"24","author":"K Yang","year":"2019","unstructured":"Yang K, Zhang S, Zhang D, Tao Q, Zhang T, Liu G, et al. Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis. Int J Clin Oncol. 2019;24:1030\u201341. https:\/\/doi.org\/10.1007\/s10147-019-01435-9. From NLM.","journal-title":"Int J Clin Oncol"},{"key":"16377_CR21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2147\/DDDT.S357483","volume":"16","author":"T Sun","year":"2022","unstructured":"Sun T, Quan W, Peng S, Yang D, Liu J, He C, et al. Network pharmacology-based strategy combined with molecular docking and in vitro validation study to explore the underlying mechanism of huo luo xiao ling dan in treating atherosclerosis. Drug Des Dev Ther. 2022;16:1621\u201345. https:\/\/doi.org\/10.2147\/DDDT.S357483. From NLM.","journal-title":"Drug Des Dev Ther"},{"key":"16377_CR22","doi-asserted-by":"publisher","unstructured":"Yuan L, Tian X, Zhang Y, Huang X, Li Q, Li W, et al. LINC00319 promotes cancer stem cell-like properties in laryngeal squamous cell carcinoma via E2F1-mediated upregulation of HMGB3. Exp Mol Med. 2021;53(1218\u201328). https:\/\/doi.org\/10.1038\/s12276-021-00647-2. From NLM.","DOI":"10.1038\/s12276-021-00647-2"},{"key":"16377_CR23","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1016\/j.jpha.2025.101203","volume":"15","author":"L Wang","year":"2025","unstructured":"Wang L, Ashrafizadeh M, Sethi G, Zhou X. pH-responsive biomimetic zeolitic imidazolate framework-based nanoparticles for co-delivery of cetuximab and siRNA in synergistic therapy of laryngeal squamous cell carcinoma. J Pharm Anal. 2025;15:101203. https:\/\/doi.org\/10.1016\/j.jpha.2025.101203. From NLM.","journal-title":"J Pharm Anal"},{"key":"16377_CR24","doi-asserted-by":"publisher","unstructured":"Psyrri A, Seiwert TY, Jimeno A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book. 2013;246\u201355. https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.246. From NLM.","DOI":"10.14694\/EdBook_AM.2013.33.246"},{"issue":"1","key":"16377_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8(1):31. https:\/\/doi.org\/10.1038\/s41392-022-01297-0. From NLM.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"16377_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1517\/14728222.2011.541440","volume":"15","author":"C Freudlsperger","year":"2011","unstructured":"Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2011;15(1):63\u201374. https:\/\/doi.org\/10.1517\/14728222.2011.541440. From NLM.","journal-title":"Expert Opin Ther Targets"},{"key":"16377_CR27","doi-asserted-by":"publisher","unstructured":"Kordbacheh F, Farah CS. Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021;13(14). https:\/\/doi.org\/10.3390\/cancers13143453. From NLM.","DOI":"10.3390\/cancers13143453"},{"issue":"8","key":"16377_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","volume":"63","author":"X Zhao","year":"2011","unstructured":"Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63(8):610\u20135. https:\/\/doi.org\/10.1016\/j.addr.2010.11.001. From NLM.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"16377_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pharmthera.2004.01.002","volume":"102","author":"JR Grandis","year":"2004","unstructured":"Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102(1):37\u201346. https:\/\/doi.org\/10.1016\/j.pharmthera.2004.01.002. From NLM.","journal-title":"Pharmacol Ther"},{"issue":"14","key":"16377_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cmdc.201600148","volume":"11","author":"WJ Scott","year":"2016","unstructured":"Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, et al. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem. 2016;11(14):1517\u201330. https:\/\/doi.org\/10.1002\/cmdc.201600148. From NLM.","journal-title":"ChemMedChem"},{"key":"16377_CR31","doi-asserted-by":"publisher","unstructured":"Li Y, Wan C, Li F, Xin G, Wang T, Zhou Q, et al. Indirubin attenuates sepsis by targeting the EGFR\/SRC\/PI3K and NF-\u03baB\/MAPK signaling pathways in macrophages. Front Pharmacol. 2025;16(1542061). https:\/\/doi.org\/10.3389\/fphar.2025.1542061. From NLM.","DOI":"10.3389\/fphar.2025.1542061"},{"key":"16377_CR32","doi-asserted-by":"publisher","unstructured":"Gurdal H, Tuglu M, Bostanabad M, Dalkili\u00e7 SY. B. Partial agonistic effect of cetuximab on epidermal growth factor receptor and src kinase activation in triple-negative breast cancer cell lines. Int J Oncol. 2019;4:1345\u201356. https:\/\/doi.org\/10.3892\/ijo.2019.4697. From NLM.","DOI":"10.3892\/ijo.2019.4697"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16377-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:03:11Z","timestamp":1788519791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16377-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16377"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16377-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1050"}}